Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.

abstract：:Efficacious antitumor immune responses must overcome multiple suppressive mechanisms in the tumor microenvironment to control cancer progression. In this study, we demonstrate that dual targeting of suppressive myeloid populations by inhibiting CSF-1/CSF-1R signaling and activation of antigen-presenting cells with ago...

journal_title：Cancer immunology research

authors： Wiehagen KR,Girgis NM,Yamada DH,Smith AA,Chan SR,Grewal IS,Quigley M,Verona RI

更新日期：2017-12-01 00:00:00

abstract：:Antibody-drug conjugates (ADC) are emerging as powerful treatment strategies with outstanding target-specificity and high therapeutic activity in patients with cancer. Brentuximab vedotin represents a first-in-class ADC directed against CD30(+) malignancies. We hypothesized that its sustained clinical responses could ...

journal_title：Cancer immunology research

authors： Müller P,Martin K,Theurich S,Schreiner J,Savic S,Terszowski G,Lardinois D,Heinzelmann-Schwarz VA,Schlaak M,Kvasnicka HM,Spagnoli G,Dirnhofer S,Speiser DE,von Bergwelt-Baildon M,Zippelius A

更新日期：2014-08-01 00:00:00

abstract：:Immune checkpoint inhibitors promote T cell-mediated killing of cancer cells; however, only a subset of patients benefit from the treatment. A possible reason for this limitation may be that the tumor microenvironment (TME) is immune privileged, which may exclude cytotoxic T cells from the vicinity of cancer cells. Th...

journal_title：Cancer immunology research

authors： Zboralski D,Hoehlig K,Eulberg D,Frömming A,Vater A

更新日期：2017-11-01 00:00:00

abstract：:Human papillomavirus type 16 (HPV16) is the etiologic factor for cervical cancer and a subset of oropharyngeal cancers. Although several prophylactic HPV vaccines are available, no effective therapeutic strategies to control active HPV diseases exist. Tumor implantation models are traditionally used to study HPV-assoc...

journal_title：Cancer immunology research

authors： Lin YH,Yang MC,Tseng SH,Jiang R,Yang A,Farmer E,Peng S,Henkle T,Chang YN,Hung CF,Wu TC

更新日期：2018-03-01 00:00:00

abstract：:Ipilimumab and radiotherapy are commonly used to treat unresectable and metastatic melanoma. Results from preclinical studies and case reports suggest a biologic interaction between these two treatments. To understand the clinical implications of the interaction, we carried out a retrospective study reviewing records ...

journal_title：Cancer immunology research

authors： Barker CA,Postow MA,Khan SA,Beal K,Parhar PK,Yamada Y,Lee NY,Wolchok JD

更新日期：2013-08-01 00:00:00

abstract：:Increased angiogenesis and tumor-induced immune evasion are two mechanisms by which clear cell renal cell carcinoma (ccRCC) proliferate and metastasize; however, the relationship between these pathways in human ccRCC is poorly understood. We conducted a nested case-control study using 98 archived tumor samples from pa...

journal_title：Cancer immunology research

authors： Joseph RW,Parasramka M,Eckel-Passow JE,Serie D,Wu K,Jiang L,Kalari K,Thompson RH,Huu Ho T,Castle EP,Cheville J,Kwon ED,Thompson EA,Parker A

更新日期：2013-12-01 00:00:00

abstract：:Inciting the cellular arm of adaptive immunity has been the fundamental goal of cancer immunotherapy strategies, specifically focusing on inducing tumor antigen-specific responses by CD8(+) cytotoxic T lymphocytes (CTL). However, there is an emerging appreciation that the cytotoxic function of CD4(+) T cells can be ef...

journal_title：Cancer immunology research

authors： Nelles ME,Moreau JM,Furlonger CL,Berger A,Medin JA,Paige CJ

更新日期：2014-11-01 00:00:00

abstract：:Macroenvironmental factors, including a patient's physical and social environment, play a role in cancer risk and progression. Our previous studies show that living in an enriched environment (EE) providing complex stimuli confers an anticancer phenotype in mice mediated, in part by a specific neuroendocrine axis, wit...

journal_title：Cancer immunology research

authors： Xiao R,Bergin SM,Huang W,Slater AM,Liu X,Judd RT,Lin ED,Widstrom KJ,Scoville SD,Yu J,Caligiuri MA,Cao L

更新日期：2016-06-01 00:00:00

abstract：:The TNF receptor family member OX40 promotes activation and proliferation of T cells, which fuels efforts to modulate this immune checkpoint to reinforce antitumor immunity. Besides T cells, NK cells are a second cytotoxic lymphocyte subset that contributes to antitumor immunity, particularly in leukemia. Accordingly,...

journal_title：Cancer immunology research

authors： Nuebling T,Schumacher CE,Hofmann M,Hagelstein I,Schmiedel BJ,Maurer S,Federmann B,Rothfelder K,Roerden M,Dörfel D,Schneider P,Jung G,Salih HR

更新日期：2018-02-01 00:00:00

abstract：:A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimumab (a human monoclon...

journal_title：Cancer immunology research

authors： Golden EB,Demaria S,Schiff PB,Chachoua A,Formenti SC

更新日期：2013-12-01 00:00:00

abstract：:Several host factors may affect the spread of cancer to distant organs; however, the intrinsic role of dendritic cells (DC) in controlling metastasis is poorly described. Here, we show in several tumor models that although the growth of primary tumors in Batf3-deficient mice, which lack cross-presenting DCs, was not d...

journal_title：Cancer immunology research

authors： Mittal D,Vijayan D,Putz EM,Aguilera AR,Markey KA,Straube J,Kazakoff S,Nutt SL,Takeda K,Hill GR,Waddell N,Smyth MJ

更新日期：2017-12-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable successes in fighting B-cell leukemias/lymphomas. Promising response rates are reported in patients treated with B-cell maturation antigen (BCMA) CAR T cells for multiple myeloma. However, responses appear to be nondurable, highlighting the need to ex...

journal_title：Cancer immunology research

authors： Globerson Levin A,Rawet Slobodkin M,Waks T,Horn G,Ninio-Many L,Deshet Unger N,Ohayon Y,Suliman S,Cohen Y,Tartakovsky B,Naparstek E,Avivi I,Eshhar Z

更新日期：2020-12-01 00:00:00

abstract：:We conducted in vitro studies and a clinical trial for patients with squamous cell carcinoma of the head and neck (SCCHN) to study the relationship between FcγRIIIa polymorphisms and antibody-dependent cellular cytotoxicity (ADCC). In vitro, FcγRIIIa genotype was correlated with ADCC and innate cytotoxicity using natu...

journal_title：Cancer immunology research

authors： Taylor RJ,Saloura V,Jain A,Goloubeva O,Wong S,Kronsberg S,Nagilla M,Silpino L,de Souza J,Seiwert T,Vokes E,Villaflor V,Cohen EE

更新日期：2015-05-01 00:00:00

abstract：:Modulating the function of immune receptors with antibodies is ushering in a new era in cancer immunotherapy. With the notable exception of PD-1 blockade used as monotherapy, immune modulation can be associated with significant toxicities that are expected to escalate with the development of increasingly potent immune...

journal_title：Cancer immunology research

authors： Gilboa E,Berezhnoy A,Schrand B

更新日期：2015-11-01 00:00:00

abstract：:Despite HER2-targeted therapies improving the outcome of HER2+ breast cancer, many patients experience resistance and metastatic progression. Cancer stem cells (CSC) play a role in this resistance and progression, thus combining HER2 targeting with CSC inhibition could improve the management of HER2+ breast cancer. Th...

journal_title：Cancer immunology research

authors： Conti L,Bolli E,Di Lorenzo A,Franceschi V,Macchi F,Riccardo F,Ruiu R,Russo L,Quaglino E,Donofrio G,Cavallo F

更新日期：2020-08-01 00:00:00

abstract：:Triple-negative breast cancer (TNBC) cells are modulated in reaction to tumor-infiltrating lymphocytes. However, their specific responses to this immune pressure are unknown. In order to address this question, we first used mRNA sequencing to compare the immunophenotype of the TNBC cell line MDA-MB-231 and the luminal...

journal_title：Cancer immunology research

authors： Noonepalle SK,Gu F,Lee EJ,Choi JH,Han Q,Kim J,Ouzounova M,Shull AY,Pei L,Hsu PY,Kolhe R,Shi F,Choi J,Chiou K,Huang TH,Korkaya H,Deng L,Xin HB,Huang S,Thangaraju M,Sreekumar A,Ambs S,Tang SC,Munn DH,Shi H

更新日期：2017-04-01 00:00:00

abstract：:Immunotherapy of immunologically cold solid tumors may require multiple agents to engage immune effector cells, expand effector populations and activities, and enable immune responses in the tumor microenvironment (TME). To target these distinct phenomena, we strategically chose five clinical-stage immuno-oncology age...

journal_title：Cancer immunology research

authors： Fabian KP,Malamas AS,Padget MR,Solocinski K,Wolfson B,Fujii R,Abdul Sater H,Schlom J,Hodge JW

更新日期：2020-12-22 00:00:00

abstract：:Ligation of GITR (glucocorticoid-induced tumor necrosis factor (TNF) receptor-related gene, or TNFRSF18) by agonist antibody has recently entered into early phase clinical trials for the treatment of advanced malignancies. Although the ability of GITR modulation to induce tumor regression is well-documented in preclin...

journal_title：Cancer immunology research

authors： Schaer DA,Budhu S,Liu C,Bryson C,Malandro N,Cohen A,Zhong H,Yang X,Houghton AN,Merghoub T,Wolchok JD

更新日期：2013-11-01 00:00:00

abstract：:Cancer immunology has recently made major therapeutic inroads that represent clinical application of basic insights into mechanisms that govern immunity against tumors. Research into fundamental elements of T-cell and natural killer-cell biology, including the basis of antigen recognition, activation, proliferation, a...

journal_title：Cancer immunology research

authors： Kim HJ,Cantor H

更新日期：2014-10-01 00:00:00

abstract：:Type I interferon (IFN-I) is a class of antiviral immunomodulatory cytokines involved in many stages of tumor initiation and progression. IFN-I acts directly on tumor cells to inhibit cell growth and indirectly by activating immune cells to mount antitumor responses. To understand the role of endogenous IFN-I in spont...

journal_title：Cancer immunology research

authors： Castiello L,Sestili P,Schiavoni G,Dattilo R,Monque DM,Ciaffoni F,Iezzi M,Lamolinara A,Sistigu A,Moschella F,Pacca AM,Macchia D,Ferrantini M,Zeuner A,Biffoni M,Proietti E,Belardelli F,Aricò E

更新日期：2018-06-01 00:00:00

abstract：:Although immune checkpoint blockade (ICB) improves clinical outcome in several types of malignancies, pancreatic ductal adenocarcinoma (PDA) remains refractory to this therapy. Preclinical studies have demonstrated that the relative abundance of suppressive myeloid cells versus cytotoxic T cells determines the efficac...

journal_title：Cancer immunology research

authors： Li J,Yuan S,Norgard RJ,Yan F,Yamazoe T,Blanco A,Stanger BZ

更新日期：2020-03-01 00:00:00

abstract：:Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates that phenotypically resemble conventional secondary lymphoid organs and are commonly found at sites of chronic inflammation. They are also found in a wide variety of primary and metastatic human tumors. The presence of tumor-associated TLS (TA-TLS) is ...

journal_title：Cancer immunology research

authors： Rodriguez AB,Engelhard VH

更新日期：2020-11-01 00:00:00

abstract：:Chronic inflammation drives colitis-associated colorectal cancer (CAC) in inflammatory bowel disease (IBD). FoxP3+ regulatory T cells (Treg) coexpressing the Th17-related transcription factor RORγt accumulate in the lamina propria of IBD patients, where they are thought to represent an intermediate stage of developmen...

journal_title：Cancer immunology research

authors： Rizzo A,Di Giovangiulio M,Stolfi C,Franzè E,Fehling HJ,Carsetti R,Giorda E,Colantoni A,Ortenzi A,Rugge M,Mescoli C,Monteleone G,Fantini MC

更新日期：2018-09-01 00:00:00

abstract：:Myeloid derived suppressor cells (MDSC) are a heterogeneous group of immature cells that accumulate in the peripheral blood and tumor microenvironment and are barriers to cancer therapy. MDSCs serve as prognostic biomarkers and are targets for therapy. On the basis of surface markers, three subsets of MDSCs have been ...

journal_title：Cancer immunology research

authors： Khan ANH,Emmons TR,Wong JT,Alqassim E,Singel KL,Mark J,Smith BE,Tario JD,Eng KH,Moysich KB,Odunsi K,Abrams SI,Segal BH

更新日期：2020-06-01 00:00:00

abstract：:T-cell receptor (TCR) gene therapy is a promising next-generation antitumor treatment. We previously developed a single-T-cell analysis protocol that allows the rapid capture of paired TCRα and β cDNAs. Here, we applied the protocol to analyze the TCR repertoire of tumor-infiltrating lymphocytes (TIL) of various cance...

journal_title：Cancer immunology research

authors： Shitaoka K,Hamana H,Kishi H,Hayakawa Y,Kobayashi E,Sukegawa K,Piao X,Lyu F,Nagata T,Sugiyama D,Nishikawa H,Tanemura A,Katayama I,Murahashi M,Takamatsu Y,Tani K,Ozawa T,Muraguchi A

更新日期：2018-04-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is a B-cell neoplasia characterized by protumor immune dysregulation involving nonmalignant cells of the microenvironment, including T lymphocytes and tumor-associated myeloid cells. Although therapeutic agents have improved treatment options for CLL, many patients still fail to resp...

journal_title：Cancer immunology research

authors： Banerjee P,Zhang R,Ivan C,Galletti G,Clise-Dwyer K,Barbaglio F,Scarfò L,Aracil M,Klein C,Wierda W,Plunkett W,Caligaris-Cappio F,Gandhi V,Keating MJ,Bertilaccio MTS

更新日期：2019-12-01 00:00:00

abstract：:Natural killer cell (NKc)-based therapies offer promising outcomes in patients with tumors, but they could improve with appropriate selection of donors and optimization of methods to expand NKcs in vitro Education through licensing interactions of inhibitory killer cell immunoglobulin-like receptors (iKIR) and NKG2A w...

journal_title：Cancer immunology research

authors： Guillamón CF,Martínez-Sánchez MV,Gimeno L,Mrowiec A,Martínez-García J,Server-Pastor G,Martínez-Escribano J,Torroba A,Ferri B,Abellán D,Campillo JA,Legaz I,López-Álvarez MR,Moya-Quiles MR,Muro M,Minguela A

更新日期：2018-12-01 00:00:00

abstract：:Colorectal cancer consists of a small number of cancer stem cells (CSC) and many non-CSCs. Although rare in number, CSCs are a target for cancer therapy, because they survive conventional chemo- and radiotherapies and perpetuate tumor formation in vivo In this study, we conducted an HLA ligandome analysis to survey HL...

journal_title：Cancer immunology research

authors： Miyamoto S,Kochin V,Kanaseki T,Hongo A,Tokita S,Kikuchi Y,Takaya A,Hirohashi Y,Tsukahara T,Terui T,Ishitani K,Hata F,Takemasa I,Miyazaki A,Hiratsuka H,Sato N,Torigoe T

更新日期：2018-03-01 00:00:00

abstract：:Proneural-to-mesenchymal transition (PMT) is a common process in glioblastoma (GBM) progression that leads to increased radiotherapy resistance. However, the mechanism underlying PMT is poorly understood. Here, we found that tumor-associated macrophages triggered PMT in glioma stem cells (GSC) via small extracellular ...

journal_title：Cancer immunology research

authors： Zhang Z,Xu J,Chen Z,Wang H,Xue H,Yang C,Guo Q,Qi Y,Guo X,Qian M,Wang S,Qiu W,Gao X,Zhao R,Guo X,Li G

更新日期：2020-07-01 00:00:00

abstract：:Pneumonitis may complicate anti-programmed death-1 (PD-1) therapy, although symptoms usually resolve with steroids. The long-term effects on respiratory function, however, are not well defined. We screened melanoma patients treated with anti-PD-1, with and without ipilimumab (anti-CTLA-4), and identified 31 patients w...

journal_title：Cancer immunology research

authors： Johnson DB,Taylor KB,Cohen JV,Ayoubi N,Haugh AM,Wang DY,Schlick BD,Voorhees AL,Gage KL,Fintelmann FJ,Sullivan RJ,Eroglu Z,Abramson RG

更新日期：2019-11-01 00:00:00